Telomir Pharmaceuticals (NASDAQ: TELO) has announced the peer-reviewed publication of preclinical data demonstrating that its lead candidate, Telomir-Zn, suppresses tumor growth in prostate and triple-negative breast cancer (TNBC) models. The findings, published in the Journal of Oncology Research and Therapy, highlight the compound's ability to selectively modulate intracellular iron and copper, leading to inhibition of histone demethylases and reactivation of tumor-suppressor genes. This research underpins the company's planned Phase 1/2 clinical trial in TNBC, which is already cleared under an active Investigational New Drug (IND) application.
The study reveals that Telomir-Zn depletes intracellular iron, thereby inhibiting histone demethylases that are crucial for cancer cell survival. This mechanism selectively kills iron-dependent TNBC cells while sparing normal cells at concentrations more than 50-fold higher. In prostate cancer models, the compound reactivated tumor-suppressor genes, further demonstrating its epigenetic modulation capabilities. These findings are significant because they provide a clear scientific rationale for targeting metal homeostasis in cancer therapy, an approach that may offer a new avenue for treating hard-to-manage tumors.
In TNBC xenograft models, Telomir-Zn reduced primary tumor size across several cell lines, including HCC1806 and BT-549, and significantly reduced metastatic dissemination in HCC1806 xenografts. Notably, combining Telomir-Zn with paclitaxel in BT-549 xenografts produced significantly greater tumor reduction than either treatment alone, suggesting potential synergistic effects with existing chemotherapy. However, MDA-MB-231 xenografts did not respond, indicating tumor-specific differences in sensitivity that will be important to consider in patient selection for future trials.
The publication of these data marks a critical milestone for Telomir as it advances Telomir-Zn toward clinical development. The company holds an active IND for a Phase 1/2 trial in patients with advanced or metastatic triple-negative breast cancer, a particularly aggressive form of breast cancer with limited treatment options. The peer-reviewed evidence provides a strong foundation for the trial, which will aim to translate these preclinical findings into clinical benefits for patients.
Telomir Pharmaceuticals is a clinical-stage biotechnology company focused on developing small-molecule therapeutics that target epigenetic and metabolic pathways implicated in cancer. Telomir-Zn, its lead program, is designed to modulate intracellular metal homeostasis and epigenetic regulation, offering a novel approach to cancer treatment. The company's progress in this area could have significant implications for the future of cancer therapy, particularly for TNBC patients who currently have few targeted options available.
For more information about Telomir Pharmaceuticals and its pipeline, visit the company's newsroom at https://ibn.fm/TELO. The full press release is available at https://ibn.fm/mv3hn.
